Bachur N R, Riggs C E, Green M R, Langone J J, Van Vunakis H, Levine L
Clin Pharmacol Ther. 1977 Jan;21(1):70-7. doi: 10.1002/cpt197721170.
In 38 adriamycin experiments and 4 daunorubicin experiments, radioimmunoassay readily and reproducibly detects and estimates these drugs and immunologically similar metabolites in patients' plasma and urine to at least 120 hr after dosing without interference by concurrent medication. The plasma drug decay follows first-order kinetics in a triphasic pattern. Radioimmunoassay and fluorescence assay show similar decay up to 4 hr but diverge at that point with the fluorescence assay yielding higher values. Pharmocokinetic differences are amplified in patients with liver dysfunction and may be caused by fluorescent drug metabolites not sensitive to radioimmunoassay or nonspecific fluorescent materials. The radioimmunoassay offers the capability to measure adriamycin and daunorubicin in clinical settings in which fluorescence assay is not available.
在38次阿霉素实验和4次柔红霉素实验中，放射免疫分析法能够轻松且可重复地检测并估算患者血浆和尿液中的这些药物以及免疫类似代谢物，给药后至少120小时内不受同时服用药物的干扰。血浆药物衰减呈三相模式遵循一级动力学。放射免疫分析法和荧光分析法在4小时内显示出相似的衰减，但此后出现分歧，荧光分析法得出的值更高。肝功能不全患者的药代动力学差异会放大，这可能是由对放射免疫分析法不敏感的荧光药物代谢物或非特异性荧光物质引起的。放射免疫分析法提供了在无法使用荧光分析法的临床环境中测量阿霉素和柔红霉素的能力。
